MVM Partners led a €32m Series A round in Avanzanite Bioscience.

MVM Partners, a global life-science private equity firm, led a €32m Series A round in Avanzanite Bioscience, an European specialty pharmaceutical company focused on rare diseases. This strategic funding will accelerate the expansion of Avanzanite’s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio.